Your browser is no longer supported. Please, upgrade your browser.
Settings
INM [NASD]
InMed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)- Insider Own0.86% Shs Outstand8.05M Perf Week15.71%
Market Cap13.04M Forward P/E- EPS next Y- Insider Trans57.12% Shs Float8.00M Perf Month-11.48%
Income- PEG- EPS next Q- Inst Own6.34% Short Float0.83% Perf Quarter-35.46%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.16 Perf Half Y-54.49%
Book/sh- P/B- EPS next Y- ROA- Target Price9.00 Perf Year-52.21%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.38 - 8.94 Perf YTD-50.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.88% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low17.39% ATR0.20
Employees13 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)44.91 Volatility16.74% 11.71%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume5.43 Prev Close1.91
ShortableYes LT Debt/Eq- EarningsSep 24 BMO Payout- Avg Volume412.21K Price1.62
Recom- SMA20-1.67% SMA50-17.24% SMA200-47.96% Volume2,239,344 Change-15.18%
Oct-22-21 12:48PM  
07:32AM  
Oct-18-21 07:02AM  
Oct-15-21 11:14AM  
Oct-13-21 04:30PM  
Sep-30-21 08:46AM  
07:30AM  
Sep-24-21 12:31PM  
07:30AM  
Sep-20-21 07:50AM  
Sep-17-21 01:14PM  
07:30AM  
Sep-13-21 11:47AM  
09:59AM  
08:43AM  
07:32AM  
07:30AM  
Sep-09-21 07:18PM  
Sep-07-21 04:04PM  
Sep-03-21 08:35AM  
Sep-02-21 08:35AM  
Aug-25-21 01:27PM  
Aug-12-21 12:00PM  
Jul-02-21 04:15PM  
Jun-29-21 07:00AM  
07:00AM  
Jun-28-21 08:35AM  
Jun-22-21 12:29PM  
Jun-21-21 08:35AM  
Jun-17-21 07:30AM  
Jun-15-21 06:41AM  
Jun-09-21 11:30AM  
May-13-21 09:15AM  
07:30AM  
May-06-21 07:30AM  
May-04-21 07:30AM  
Apr-28-21 07:30AM  
Apr-27-21 07:30AM  
Apr-26-21 07:30AM  
Mar-17-21 02:49PM  
Mar-03-21 06:00PM  
Feb-26-21 08:00AM  
Feb-16-21 07:30AM  
Feb-11-21 09:30AM  
07:30AM  
07:30AM  
Feb-08-21 07:04AM  
Feb-05-21 09:00PM  
12:15PM  
09:53AM  
09:37AM  
09:34AM  
09:34AM  
Feb-02-21 07:00AM  
Feb-01-21 05:00AM  
Jan-26-21 08:00AM  
Jan-19-21 02:00PM  
Jan-18-21 07:00AM  
Jan-08-21 07:30AM  
07:30AM  
Jan-05-21 04:52PM  
Dec-11-20 07:00AM  
Nov-25-20 07:30AM  
Nov-24-20 08:00PM  
Nov-18-20 07:30AM  
07:30AM  
Nov-17-20 06:00AM  
Nov-16-20 11:42AM  
Nov-13-20 07:30AM  
Nov-12-20 09:10AM  
09:10AM  
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAMS ERIC APresident & CEOSep 29Buy1.738,80015,22436,283Sep 30 01:39 PM
ADAMS ERIC APresident & CEOSep 28Buy1.7511,40019,98427,483Sep 29 02:00 PM
COLWILL BRUCECFOSep 28Buy1.775,0008,8406,515Sep 29 01:59 PM